In 2025, the biotech sector faced significant uncertainty characterized by ongoing funding challenges and the complexities of drug development. A survey of 163 biotech leaders revealed key insights, highlighting that while funding remains a concern, 75% of leaders intend to boost their R&D spending in the next two years, with a noticeable shift towards larger deals and partnerships with major pharmaceutical companies. China’s emergence as a leader in innovative drug development is underscored by its increasing number of clinical trials and the expectation that its biologics will constitute a significant portion of future FDA approvals. The survey also noted changes in focus areas, with cell therapies and microbiome treatments gaining traction, while oncology’s prominence has declined. A growing concern for leaders is geopolitical uncertainty and evolving regulatory environments, which are impacting their operations and strategy. Despite these challenges, the majority of biotech leaders expressed confidence in achieving future investment milestones and the success of their products, with patients remaining the ultimate beneficiaries of their innovations.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.pharmexec.com/view/ambition-ambiguity-trends-sentiments-shaping-biotech-2026
